Atomoxetine Beyond ADHD: A Fact or Artifact

Ahmed Naguy¹, Ali Al-Tajali²

¹Al-Manara Centre for CAP, Kuwait Centre for Mental Health (KCMH), Shuwaikh, State of Kuwait
²General Adult Psychiatrist, Head of Neuromodulation Unit, KCMH, Shuwaikh, State of Kuwait

Email address: ahmednagy@hotmail.co.uk (A. Naguy)


Abstract: Atomoxetine is FDA-approved in Attention-Deficit/Hyperactivity Disorder (ADHD) with demonstrable efficacy and reasonable tolerability. It is classically a selective norepinephrine reuptake inhibitor but data accrues suggestive of an attractive pharmacologic portfolio speaking to the idea of a pluripotent psychotropic agent beyond ADHD. Heaps of cases in the literature abound portraying a multitude of indications with variable level of evidence oscillating from strong to only flimsy. Here, we shed light on these uses and testing extant evidence.

Keywords: Atomoxetine-Pharmacology-Clinical Uses-Off Label Uses

1. Introduction

Atomoxetine is a selective norepinephrine reuptake inhibitor (NRI), a non-stimulant that is FDA-approved for attention-deficit hyperactivity disorder (ADHD) in children above age of 6, adolescents and adults. It is effective and generally well tolerated. It is significantly more effective than placebo and is not inferior to immediate-release methylphenidate. However, it is significantly less effective than the extended-release methylphenidate formulation, and extended-release mixed amphetamine salts. Atomoxetine can be administered either as a single daily dose or split into two evenly divided doses, has a negligible risk of abuse, and is not a controlled substance due to lack of effect on nucleus accumbens. Atomoxetine is particularly useful for patients at risk of substance abuse, as well as those who have co-morbid anxiety or tics, or when multiple dosing regimens are not practically feasible.

As outlined in the next section, the pharmacologic portfolio of atomoxetine is attractive and portends a pluripotent psychotropic agent that goes beyond ADHD.

This translates clinically into a multitude of indications and cases in the literature abound highlighting panoply of uses. This paper sheds light on some of these and available evidence.

2. Pharmacology of Atomoxetine

Atomoxetine inhibits norepinephrine transporter (NET). It increases NE and dopamine (DA) by 3-folds in prefrontal cortex but not in the nucleus accumbens and hence, low potential for abuse. Atomoxetine has been shown to greatly occupy both NET and serotonin transporter (SERT) at clinically relevant doses. Also, atomoxetine has been demonstrated to block NMDA-Glut in clinically relevant concentrations.

Moreover, atomoxetine inhibits G-protein-coupled inwardly rectifying potassium channels (GIRK); modulation of which has been proposed as a potential treatment for several neuropsychiatric disorders.

Its major metabolite, 4-hydroxyatomoxetine, has been reported to be mu-opiate antagonist and kappa-opiate partial agonist.

Table 1 summarizes these proposed mechanisms.

<table>
<thead>
<tr>
<th>ATX proposed mechanism(s) of action. (on page2)</th>
</tr>
</thead>
<tbody>
<tr>
<td>NRI</td>
</tr>
<tr>
<td>DRI</td>
</tr>
<tr>
<td>SERT inhibition</td>
</tr>
<tr>
<td>NMDA-Glut Antagonist</td>
</tr>
<tr>
<td>GIRK inhibition</td>
</tr>
<tr>
<td>κ opiate partial agonist</td>
</tr>
</tbody>
</table>

This composite mechanism of action would signal a pluripotent agent with wide array of indications in clinical practice as we would see in next sections.
3. Atomoxetine Beyond ADHD

Apart from the only formal indication of atomoxetine in ADHD, it has been tried in a multitude of clinical indications, although evidence for these is highly variable. Its proper use in practice as off-label would be the onus of nimble clinicians and only after exhausting other alternatives at hand with more solid evidence base.

Suffice to say that atomoxetine has been tried, inter alia, for depression, binge-eating disorder, freezing-of-gait in Parkinson’s disease (PD), cognitive domain in schizophrenia and Huntington’s disease (HD) and substance use disorders (SUD), only to name few.

4. Atomoxetine in Depression

Reboxetine, a chemically related agent, is an NRI antidepressant.

And as outlined in the section of ATX pharmacology, it inhibits NET, DAT and SERT and this would portend a robust antidepressant activity, at least theoretically.

Kraotchvil et al. compared atomoxetine monotherapy to combined treatment with fluoxetine in ADHD with comorbid depression and anxiety. In this study, reductions of ADHD, depression and anxiety were marked for both treatment groups.

Berigan reported 3 cases of MDD responding to SSRI treatment that achieved remissions with adjunctive atomoxetine especially in residual noradrenergic symptoms of fatigue, anergia and aproaxia.

On the other hand, Michelson et al. conducted a randomized, double-blind, placebo-controlled study for add-on atomoxetine in MDD inadequately responsive to sertraline and it was negative.

Weintraub et al. assessed efficacy of atomoxetine for depression and other neuropsychiatric symptoms of fatigue, anergia and aproaxia. In this study, atomoxetine helped with global cognitive performance and daytime sleepiness but not depression.

Ravindran et al. conducted a randomized, double-blind, placebo-controlled trial of atomoxetine involving 27 patients with social anxiety disorder-generalized subtype without comorbid depression and anxiety. In this study, reductions of ADHD, combined treatment with fluoxetine in ADHD with comorbid depression and anxiety were marked for both treatment groups.

Ravindran et al. conducted a randomized, double-blind, placebo-controlled trial of atomoxetine involving 27 patients with social anxiety disorder-generalized subtype without comorbid depression and anxiety. In this study, reductions of ADHD, combined treatment with fluoxetine in ADHD with comorbid depression and anxiety were marked for both treatment groups.

5. Atomoxetine in Binge-Eating Disorder

Lisdexamfetamine dimesylate, a stimulant prodrug, is recently FDA-approved for binge-eating disorder (BED).

Anorexigenic effect of ATX could be contributory.

McElroy et al. conducted a 10-week, single-centre, randomized, double-blind, placebo-controlled, flexible-dose trial of atomoxetine for BED. In this study, atomoxetine was efficacious and fairly well-tolerated in the short-term.

To extrapolate, Ball et al. conducted a 24-week randomized, placebo-controlled trial of atomoxetine for weight reduction in patients with schizophrenia or schizoaffective disorder on olanzapine or clozapine who gained at least 7% from baseline but was negative.

6. Atomoxetine in Schizophrenia

Freidman et al. conducted a pilot study of adjunctive atomoxetine treatment to atypical antipsychotics for cognitive deficits in schizophrenia. In this study, no significant cognitive improvement was associated with atomoxetine treatment. However, atomoxetine treatment was associated with significantly greater increases in working memory-related activation of the left dorsolateral prefrontal and left posterior cingulate cortices.

Kelly et al. conducted a randomized double-blind trial of atomoxetine for cognitive impairments in 32 patients with schizophrenia but was negative.

We reported a case of early-onset schizophrenia where add-on ATM mitigated negative and cognitive domains, disorganized symptom cluster and atypical antipsychotic-induced weight gain. We assume that boosting the noradrenergic tone with subsequent disinhibition of dopamine projections to medial prefrontal cortex could rectify the hypofrontality underlying negative deficits, in tandem with reports of efficacy of nor-adrenergic agents in negative domain schizophrenia.

Poyurovsky et al. enrolled 59 first-episode schizophrenic patients on olanzapine 10 mg/d in a randomized double-blind placebo-controlled study to receive either reboxetine, a congener of ATX, or placebo for 6 weeks. Appetite increase was significantly lower in the olanzapine/reboxetine than olanzapine/placebo group and was correlated with attenuation of weight gain. Reboxetine addition was safe and well-tolerated.

7. Atomoxetine in Parkinson Disease

Freezing of gait is one of the most troublesome symptoms associated with Parkinson disease (PD) which usually does not respond to dopaminergic therapy, possibly because it is mediated via noradrenergic, rather than dopaminergic, deficiency.

Jankovic enrolled 5 patients with gait disturbance into a double-blind randomized trial of atomoxetine. Improvement in total Gait and Balance Scale score was noted in those treated with atomoxetine but did not reach statistical significance.

12 patients with PD and disabling executive dysfunction (ED) completed an 8-week pilot open-label, flexible dose trial of ATX. On primary outcome measures, it was associated with improved ED based on the Clinical Global Impression-Change Scale and behavioral measures of ED (Frontal Systems Behavior Scale Executive Dysfunction and Connors Adult ADHD Rating Scale inattention/memory subscales).

As shown in the section of depression, ATX helped with global cognitive performance and daytime sleepiness in PD but not depression.

8. Atomoxetine in Huntington Disease

A 10-week randomized, double-blind, cross-over of 20 patients with mild Huntington Disease (HD) of atomoxetine
for cognitive dysfunction was negative.\textsuperscript{20}
Similarly, Mohs et al.\textsuperscript{21} conducted a 6-month, randomized, double-blind, placebo-controlled, parallel trial of ATX augmentation of acetylcholinesterase inhibitor therapy in patients with AD. It was generally well-tolerated but did not significantly improve cognitive function.

9. Atomoxetine in Autism
Arnold et al.\textsuperscript{22} conducted a placebo-controlled cross-over pilot study of atomoxetine in hyperkinetic ASD. Atomoxetine was superior to placebo on the hyperactivity subscale of aberrant behaviour checklist.

10. Atomoxetine in Nocturnal Enuresis
Sumner et al.\textsuperscript{23} conducted an outpatient, multicenter, randomized, double-blind, parallel, placebo-controlled study involving 87 pediatric subjects on the effects of atomoxetine on bladder control in children with nocturnal enuresis (NE). Atomoxetine treatment was associated with a significant increase in dry nights in children with nocturnal enuresis.
Shatkin\textsuperscript{24} earlier reported 4 cases of ADHD with comorbid NE treated with ATX and all experienced serendipitous resolution of NE.
Stimulation of the alpha-adrenergic receptors promotes urinary continence via contraction of the bladder trigone and internal sphincter. Stimulation of beta-receptors in the bladder result in smooth muscle relaxation of the bladder wall. Thus, sympathetic stimulation causes bladder wall relaxation and internal urethral-sphincter contraction resulting in urinary continence.\textsuperscript{25} This could explain role of ATX in treatment of NE.

11. Conclusion
Data from literature robustly supports use of atomoxetine with growing body of evidence in Bing-eating disorder, nocturnal enuresis, hyperkinetic autism, but less so for freezing-of-gait in Parkinson disease. Mixed data exists for ATX use in depression. And its use as a cognitive enhancer in schizophrenia, PD, HD and AD was futile.
Having said so, it remains incumbent on the clinician’s part to decide when using ATX in these off-label indications only after exhausting other options with more solid evidence-base.

References


